Boehringer-Ingelheim
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Boehringer Ingelheim GmbH | |
|---|---|
| Image:Bilogo new.jpg | |
| Type | Pharmaceuticals/Private |
| Founded | Germany (1885) |
| Headquarters | Binger Str. 173 55216 Ingelheim Germany |
| Key people | Dr. Alessandro Banchi, Chairman Dr Andreas Barner, Vice Chairman Professor Marbod Muff, Head of Finance Dr Hans-Jürgen Leuchs, Head of Operations |
| Industry | Pharmaceuticals |
| Products | Medicines, ie. Aggrenox, Flomax, Micardis |
| Revenue | ▲€9.535 billion EUR (2005) |
| Operating income | ▲€1.923 billion EUR (2005) |
| Net income | ▲€1.514 billion EUR (2005) |
| Employees | 37,406 (2005) |
| Slogan | Value through Innovation |
| Website | http://www.boehringer-ingelheim.com |
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for around 95% of sales. This includes prescription medicines and consumer healthcare products.
Contents |
History
The company was founded in 1885 during the Gründerzeit by the German chemist Dr Albert Boehringer. Initially it produced tartaric acid from wine yeast in a small factory in Ingelheim, together with 20 employees. Today, 120 years later, the Boehringer Ingelheim group is one of the world's top 20 pharmaceutical companies. For some years now, Boehringer Ingelheim has been one of the fastest-growing companies in the pharmaceutical industry and one of the world's largest manufacturers of biopharmaceuticals for industrial customers. Boehringer Ingelheim currently has 143 affiliated companies in and outside Germany.
Fields of activity
Boehringer Ingelheim researches, develops, manufactures and supplies pharmaceuticals and biopharmaceuticals. The primary focus is on Human Pharmaceuticals, including treatments for respiratory, cardiovascular, central nervous system, urological and viral disorders. In addition the research has been intensified into the immune system, metabolic diseases, and cancer. Oncology is new among Boehringer Ingelheim’s indication areas.
Boehringer Ingelheim Pharma Chemicals has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years. The mission of the Product Unit RESOMER® within Boehringer Ingelheim Phama Chemicals Division is to develop, produce, and sell monomers and biodegradable polymers for the production of medical devices or pharmaceutical formulations.
Operational and development sites
The company's largest site and corporate headquarters is located in Ingelheim am Rhein near Mainz and Frankfurt, Germany. However, Boehringer Ingelheim is a globally operating company, with almost 150 subsidiaries around the globe. Their main business regions are Europe, North America and Asia.
As of December 2005, the Boehringer Ingelheim group of companies had nearly 37,500 employees worldwide. Of these, around 30% worked in production, 37% in marketing and sales and 16% in research and development. In Germany, Belgium, Brazil, the Netherlands, Switzerland and the United Kingdom, Boehringer Ingelheim has received recognition as one of the best employers. For example, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For. In 2006 the Science magazine (US) put Boehringer Ingelheim at the 2nd place of the top employers in the biotechnology and pharmaceutical industries.[1].
Key product lines
- Aggrenox ®
- Antistax ®
- Bisolvon ® (available in the Philippines) also
- Buscopan ®
- Buscapina ®
- Dulcolax ®
- Flomax ®
- Micardis ®
- Mirapex ®
- Mucosolvan ®
- Mucoangin ®
- Mobic ®
- Spiriva ®
- Pharmaton ®
- Resomer ®
- Metacam ®
- Vetmedin ®
Notes
- ↑ Gwynne, Peter (October 20 2006), "TOP EMPLOYER SURVEY: It All Starts with Science",Science. Retrieved August 26 2007
External links
- Boehringer Ingelheim Corporate website
- Boehringer Ingelheim Company Profile and News Archive
- Boehringer Ingelheim Corporate Profile
- Boehringer Ingelheim We care website
- Boehringer Ingelheim Argentina
- Boehringer Ingelheim (Canada) Ltd.
- Boehringer Ingelheim Resomer productsde:Boehringer Ingelheimit:Boehringer Ingelheimsv:Boehringer Ingelheim
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
